U.S., Sept. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07162181) titled 'Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers' on Aug. 29.
Brief Summary: The purpose of this study is to find out more about the long-term safety of pirtobrutinib in participants with previously treated types of blood cancer. Participants must have chronic lymphocytic leukemia, small lymphocytic lymphoma, or non-Hodgkins lymphoma. The study is open to those who completed the original study - J2N-MC-JZNJ (NCT04849416) and continue to benefit from treatment. Treatment will be given every 12 weeks and this study is expected to last about 5 years.
Study Start Date: Aug. 07
Study Typ...